Multiomic profiling of LRRC15 in triple negative breast cancer (TNBC). A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) ...

A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Researchers from USask have identified a potential target for eliminating breast cancer cells. The team was led by Dr. Franco Vizeacoumar (Ph.D.) and Dr. Andrew Freywald (Ph.D.) with USask and the ...

The epigenetic/anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified ...

CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the United States Patent and Trademark Office ...

Detailed price information for Cyclacel Pharmaceuti (CYCC-Q) from The Globe and Mail including charting and trades.

Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered ...

PLK1-dependent chromatin-cytoplasmic shuttling of 53BP1 during mitotic delays has been described previously (PMID: 38547292, 37888778). These papers are cited in the text, but the main conclusions of ...